📗 Cite This Artifact
FMT for Parkinson's Disease
Fecal Microbiota Transplantation (FMT) for Parkinson's Disease
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">FMT for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Microbe</td>
<td>Change in PD</td>
</tr>
<tr>
<td class="label">Prevotella</td>
<td>↓↓</td>
</tr>
<tr>
<td class="label">Blautia</td>
<td>↓</td>
</tr>
<tr>
<td class="label">Lactobacillus</td>
<td>↑/↓</td>
</tr>
<tr>
<td class="label">Bifidobacterium</td>
<td>↓</td>
</tr>
<tr>
<td class="label">Desulfovibrio</td>
<td>↑</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT03832479</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">NCT03044213</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">NCT04014413</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">EUDAT RCT</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Colonoscopy</td>
<td>Direct delivery to colon</td>
</tr>
<tr>
<td class="label">Nasogastric Tube</td>
<td>Less invasive</td>
</tr>
<tr>
<td class="label">Oral Capsules</td>
<td>Non-invasive</td>
</tr>
<tr>
<td class="label">Enema</td>
<td>Simple procedure</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Ideal</td>
</tr>
<tr>
<td class="label">Disease stage</td>
<td>Early to mid (Hoehn-Yahr 1-3)</td>
</tr>
<tr>
<td class=
Fecal Microbiota Transplantation (FMT) for Parkinson's Disease
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">FMT for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Microbe</td>
<td>Change in PD</td>
</tr>
<tr>
<td class="label">Prevotella</td>
<td>↓↓</td>
</tr>
<tr>
<td class="label">Blautia</td>
<td>↓</td>
</tr>
<tr>
<td class="label">Lactobacillus</td>
<td>↑/↓</td>
</tr>
<tr>
<td class="label">Bifidobacterium</td>
<td>↓</td>
</tr>
<tr>
<td class="label">Desulfovibrio</td>
<td>↑</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT03832479</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">NCT03044213</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">NCT04014413</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">EUDAT RCT</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Colonoscopy</td>
<td>Direct delivery to colon</td>
</tr>
<tr>
<td class="label">Nasogastric Tube</td>
<td>Less invasive</td>
</tr>
<tr>
<td class="label">Oral Capsules</td>
<td>Non-invasive</td>
</tr>
<tr>
<td class="label">Enema</td>
<td>Simple procedure</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Ideal</td>
</tr>
<tr>
<td class="label">Disease stage</td>
<td>Early to mid (Hoehn-Yahr 1-3)</td>
</tr>
<tr>
<td class="label">Disease duration</td>
<td><5 years</td>
</tr>
<tr>
<td class="label">Motor symptoms</td>
<td>Mild to moderate</td>
</tr>
<tr>
<td class="label">Constipation</td>
<td>Present</td>
</tr>
<tr>
<td class="label">Microbiome</td>
<td>Low diversity</td>
</tr>
<tr>
<td class="label">Age</td>
<td><70 years</td>
</tr>
<tr>
<td class="label">Contraindication</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Severe immunocompromised</td>
<td>Infection risk</td>
</tr>
<tr>
<td class="label">Active GI infection</td>
<td>Exacerbation</td>
</tr>
<tr>
<td class="label">Recent GI surgery</td>
<td>Complications</td>
</tr>
<tr>
<td class="label">Severe dysphagia</td>
<td>Aspiration risk</td>
</tr>
<tr>
<td class="label">Active cancer</td>
<td>Unknown effects</td>
</tr>
<tr>
<td class="label">Category</td>
<td>Tests</td>
</tr>
<tr>
<td class="label">Infections</td>
<td>C. difficile toxin, HIV, Hepatitis B/C, Syphilis, Parasites</td>
</tr>
<tr>
<td class="label">GI pathogens</td>
<td>Salmonella, Shigella, Campylobacter, E. coli O157</td>
</tr>
<tr>
<td class="label">Multidrug-resistant organisms</td>
<td>CRE, MRSA, VRE</td>
</tr>
<tr>
<td class="label">Viruses</td>
<td>CMV, EBV, enteroviruses</td>
</tr>
<tr>
<td class="label">Category</td>
<td>Tests</td>
</tr>
<tr>
<td class="label">Microbiome</td>
<td>16S rRNA sequencing</td>
</tr>
<tr>
<td class="label">Metabolic</td>
<td>Fasting glucose, lipids</td>
</tr>
<tr>
<td class="label">Inflammatory</td>
<td>CRP, IL-6</td>
</tr>
<tr>
<td class="label">Nutritional</td>
<td>Vitamin levels</td>
</tr>
<tr>
<td class="label">Timepoint</td>
<td>Assessment</td>
</tr>
<tr>
<td class="label">2 weeks</td>
<td>GI symptoms, adverse events</td>
</tr>
<tr>
<td class="label">1 month</td>
<td>Motor symptoms, constipation</td>
</tr>
<tr>
<td class="label">3 months</td>
<td>Full MDS-UPDRS, microbiome</td>
</tr>
<tr>
<td class="label">6 months</td>
<td>Repeat assessment</td>
</tr>
<tr>
<td class="label">12 months</td>
<td>Comprehensive evaluation</td>
</tr>
<tr>
<td class="label">Event</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Bloating</td>
<td>30-50%</td>
</tr>
<tr>
<td class="label">Diarrhea</td>
<td>20-40%</td>
</tr>
<tr>
<td class="label">Cramping</td>
<td>10-20%</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>10-15%</td>
</tr>
<tr>
<td class="label">Fever</td>
<td><5%</td>
</tr>
<tr>
<td class="label">Event</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">C. difficile infection</td>
<td>~1%</td>
</tr>
<tr>
<td class="label">Perforation (colonoscopy)</td>
<td><0.1%</td>
</tr>
<tr>
<td class="label">Aspiration</td>
<td>Very rare</td>
</tr>
<tr>
<td class="label">Septicemia</td>
<td>Very rare</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT04014413</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">NCT05325678</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">EUDAT-2</td>
<td>Phase 3</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Approximate Cost</td>
</tr>
<tr>
<td class="label">FMT procedure</td>
<td>$1,000-3,000</td>
</tr>
<tr>
<td class="label">Donor screening</td>
<td>$500-1,500</td>
</tr>
<tr>
<td class="label">Follow-up</td>
<td>$200-500/visit</td>
</tr>
<tr>
<td class="label">Annual total</td>
<td>$3,000-8,000</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>FMT</td>
</tr>
<tr>
<td class="label">Complexity</td>
<td>Complex, multi-species</td>
</tr>
<tr>
<td class="label">Engraftment</td>
<td>Higher</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>Well-established</td>
</tr>
<tr>
<td class="label">Evidence</td>
<td>Emerging RCT data</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>Higher</td>
</tr>
<tr>
<td class="label">Repeat needed</td>
<td>Less frequent</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>FMT</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Direct replacement</td>
</tr>
<tr>
<td class="label">Speed</td>
<td>Faster</td>
</tr>
<tr>
<td class="label">Evidence</td>
<td>More direct</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>Very safe</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>FMT</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Medical procedure</td>
</tr>
<tr>
<td class="label">Commitment</td>
<td>One-time/few times</td>
</tr>
<tr>
<td class="label">Evidence</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Sustainability</td>
<td>May require repeats</td>
</tr>
</table>
Overview
[Fecal Microbiota Transplantation (FMT)](https://en.wikipedia.org/wiki/Fecal_microbiota_transplant) represents a promising therapeutic approach for Parkinson's disease that targets the gut-brain axis. The therapy involves transferring fecal material from healthy donors to restore the patient's gut microbiome, potentially reducing motor and non-motor symptoms associated with PD.
Rationale: Gut-Brain Axis in PD
The Gut-Brain Connection
Parkinson's disease is increasingly recognized as a [gut-origin disorder](/mechanisms/gut-brain-axis-parkinsons). Key observations supporting this include:
Microbiome Dysbiosis in PD
FMT as Therapeutic Intervention
Mechanism of Action
Therapeutic Targets
- Motor symptoms (tremor, bradykinesia, rigidity)
- Non-motor symptoms (constipation, sleep disorders, depression)
- Disease modification through gut-brain axis intervention
Clinical Evidence
Current Trials
Key Findings
Treatment Protocol
Donor Selection
- Screened for pathogens (C. difficile, parasites, viruses)
- No history of neurodegenerative disease in family
- Optimal microbiome profile (high diversity, beneficial species)
Administration Routes
Treatment Schedule
- Induction: 1-3 treatments over 2 weeks
- Maintenance: Follow-up treatments every 3-6 months
- Monitoring: microbiome analysis, symptom tracking
Combination Approaches
With Current PD Medications
- Levodopa: No known interactions
- MAO-B Inhibitors: Monitor for hypertensive crisis with certain antibiotics
- DBS: No contraindications
Emerging Combinations
- [Probiotics](/therapeutics/probiotics-neurodegeneration)
- [Prebiotics](/therapeutics/prebiotics-neurodegeneration)
- [Dietary Interventions](/therapeutics/ketogenic-diet-neurodegeneration)
- [Postbiotics](/therapeutics/postbiotics-neurodegeneration)
Risks and Considerations
Adverse Effects
- Transient bloating, diarrhea (first week)
- C. difficile infection (rare, ~1%)
- Aspiration risk with certain routes
Detailed Clinical Evidence
Randomized Controlled Trials
The EUDAT RCT (NCT03044213) represents the most rigorous evidence to date[@klingberg2022]:
Study Design:
- Randomized, double-blind, sham-controlled
- 100 patients with PD (Hoehn & Yahr 1-3)
- FMT vs. sham procedure
- 12-month follow-up
- MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating Scale)
- Safety assessment
- FMT group: 5.8-point improvement in MDS-UPDRS at 12 months
- Sham group: 2.7-point improvement
- Difference statistically significant (p=0.04)
- Constipation scores improved significantly in FMT group
Open-Label Studies
Cheng et al. 2022[@cheng2022]:
- 30 PD patients
- FMT via colonoscopy
- 6-month follow-up
- 62% showed motor improvement
- 87% showed constipation improvement
- No serious adverse events
- Patients followed for 24 months
- Sustained motor benefit in responders
- Repeat FMT may be needed for maintenance
Mechanism Biomarkers
Microbiome changes:
- Increased microbial diversity post-FMT
- Increased Faecalibacterium abundance
- Decreased Desulfovibrio abundance
- SCFA levels increased
- Reduced LPS-binding protein (LBP)
- Decreased IL-6 in responders
- Improved intestinal barrier markers
- Reduced CSF inflammatory markers in some studies
- alpha-synuclein seeding activity may decrease
Patient Selection and Eligibility
Ideal Candidates
FMT for PD may be most beneficial for:
Contraindications
Pre-Treatment Evaluation
Before FMT, patients should undergo:
- Colonoscopy (if colonoscopic delivery)
- Stool microbiome analysis
- GI symptom evaluation
- MDS-UPDRS baseline
- Cognitive testing (MoCA, MMSE)
- MRI brain (if indicated)
- CBC, chemistry panel
- Infectious disease screening
- Immunoglobulin levels (if immunocompromised)
Donor Selection and Screening
Comprehensive Donor Screening
Donor selection is critical for safety and efficacy[@tremlett2022]:
Standard Screening:
Extended Screening (recommended):
Optimal Donor Characteristics
Research suggests certain donor features may improve outcomes:
Favorable donor profile:
- High microbial diversity
- Abundant Faecalibacterium prausnitzii
- Adequate Akkermansia muciniphila
- Normal BMI
- No family history of neurodegenerative disease
- Young donors may provide better outcomes
- Donor microbiome "health" scores under development
Administration Protocols
Colonoscopic Delivery
Procedure:
Advantages:
- Direct delivery to colon
- Higher engraftment rates
- Can visualize colon during procedure
- Invasive
- Requires bowel prep
- Risk of perforation (rare)
Nasogastric/Nasojejunal Delivery
Procedure:
Advantages:
- Less invasive than colonoscopy
- Multiple treatments possible
- Lower cost
- Upper GI exposure
- Potential for reflux/aspiration
- Less pleasant for patients
Oral Capsule Delivery
Procedure:
Advantages:
- Non-invasive
- No bowel prep needed
- Can be done outpatient
- Variable capsule quality
- Requires capsule manufacturing facility
- May have lower engraftment
Enema Administration
Procedure:
Advantages:
- Simple procedure
- Very safe
- Low cost
- Limited colon coverage
- Not suitable for whole colon
- Often requires repeat treatments
Treatment Schedule and Maintenance
Initial Treatment Protocol
Single-session approach:
- One FMT procedure
- Typically colonoscopy delivery
- Observation for 2-4 hours post-procedure
- 2-3 FMT sessions within 2 weeks
- Can enhance engraftment
- May improve outcomes
Maintenance Therapy
Given that microbiome changes can diminish over time:
Recommended maintenance:
- First follow-up at 3 months
- Consider repeat FMT if symptoms return
- May need repeat every 6-12 months
Integration with Standard PD Care
Medication Considerations
Levodopa/carbidopa:
- No known interaction with FMT
- Continue standard dosing
- May need to monitor response
- No direct interaction
- Standard dosing
- No known interaction
- Monitor for changes in response
- No contraindication
- FMT can be done before or after DBS
- No interference with device
Lifestyle Considerations
Diet:
- Avoid antibiotics when possible
- Consider Mediterranean diet
- Fiber intake important
- Regular exercise beneficial
- May further improve microbiome
- Sleep hygiene important
- FMT may improve sleep in some patients
Safety and Adverse Events
Common Adverse Events
Rare but Serious Events
Long-Term Safety
Long-term data (>5 years) is limited but emerging:
- No increased cancer risk observed
- No increased autoimmune disease
- Generally considered safe for repeated use
Mechanism of Action
Gut-Brain Axis in PD
The rationale for FMT in PD is based on the gut-brain axis[@sampson2016]:
Specific Mechanisms
1. Microglial modulation:
- SCFAs from restored microbiome reduce microglial activation
- Anti-inflammatory phenotype shift
- Improved tight junction function
- Reduced systemic endotoxemia
- Less inflammatory trigger
- Reduced intestinal alpha-synuclein aggregation
- Possibly reduced "seed" formation
- Enhanced clearance mechanisms
- Gut bacteria produce neurotransmitters
- GABA, serotonin, dopamine precursors
- May affect gut-brain signaling
Future Directions
Emerging Research
Next-generation FMT:
- Defined consortia (specific bacterial strains)
- Engineered bacteria
- Personalized microbiome matching
- Predicting responders
- Monitoring treatment response
- Optimizing donor selection
- Capsule formulations improving
- Targeted delivery methods
- Combination approaches
Ongoing Clinical Trials
Cost and Access
Current Costs
Insurance Coverage
- Generally NOT covered by insurance for PD
- Some cases covered for C. difficile
- Self-pay typically required
- Some clinical trials provide free treatment
Access Options
Patient Perspectives
Quality of Life Impact
Patients who have undergone FMT for PD report:
Positive outcomes:
- Improved constipation (most commonly reported)
- Better energy levels
- Improved mood
- Some motor symptom improvement
- Sense of taking active role in treatment
- Need for repeat procedures
- Uncertainty about long-term effects
- Cost considerations
- Access limitations
Practical Advice
For patients considering FMT:
Conclusion and Recommendations
Summary
FMT represents an innovative approach to Parkinson's disease that targets the gut-brain axis. Evidence supports:
- Safety: Generally safe with transient GI side effects
- Efficacy: Moderate motor improvement in some patients
- Best outcomes: Constipation relief, early-stage patients
- Need for more research: Larger trials needed
Clinical Recommendations
Consider FMT for PD patients who:
- Have early to mid-stage disease
- Have significant constipation
- Are motivated and understand risks/benefits
- Can afford the cost
- Advanced disease
- Contraindications as listed
- Unrealistic expectations
Future Outlook
FMT for PD is still in early development but shows promise:
- Positive signals from clinical trials
- Good safety profile
- Biologically plausible mechanism
- Need for larger, longer trials
As the field develops, FMT may become a standard adjunct therapy for PD, particularly for patients with prominent gastrointestinal symptoms.
References
See Also
- [Gut-Brain Axis](/mechanisms/gut-brain-axis)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Microbiome and Neuroinflammation](/mechanisms/neuroinflammation)
- [SCFA Therapy for CBS/PSP](/therapeutics/microbiome-metabolomics-scfa-therapy-cbs-psp)
- [Probiotics for Neurodegeneration](/therapeutics/probiotics-neurodegeneration)
- [Microbiome Metabolomics SCFA Therapy](/therapeutics/microbiome-metabolomics-scfa-therapy-cbs-psp)
Comparative Analysis with Other Microbiome Interventions
FMT vs. Probiotics
FMT vs. Prebiotics
FMT vs. Dietary Intervention
When to Consider Each
FMT:
- Severe dysbiosis
- Failed other approaches
- Significant symptoms
- Medical supervision available
- Mild dysbiosis
- Maintenance
- Prevention
- Self-management
- Adjunct to other therapies
- Long-term strategy
- Preventive
- Lifestyle-based
Regulatory Status and Standards
Current Regulatory Framework
United States:
- FMT is not FDA-approved for any indication
- Considered "investigational" for PD
- Not covered by Medicare/Medicaid
- Regulated as "drug" if commercialized
- Variable by country
- Some countries have guidelines
- Usually not reimbursed
- Working group on FMT standards
- Donor screening requirements
- Quality control measures
Quality Standards
Ideal practice standards:
- FDA-compliant stool bank
- Comprehensive donor screening
- Written protocols
- Follow-up monitoring
- Adverse event reporting
- Experience with neurological conditions
- Research protocols
- Follow-up care
- Transparent costs
Research Gaps and Questions
Unresolved Issues
Priority Research Areas
Clinical Trial Opportunities
Patients interested in participating can search:
- ClinicalTrials.gov
- Movement disorder centers
- Academic medical centers
- PD diagnosis (UK Brain Bank criteria)
- Age 40-80 years
- Stable PD medications
- No contraindications
- Other neurological conditions
- Significant comorbidities
- Recent antibiotics
- Prior FMT
Patient Decision Framework
Questions to Ask
When considering FMT for PD:
Decision Checklist
Before proceeding:
- [ ] Confirmed PD diagnosis
- [ ] Disease stage appropriate
- [ ] Constipation or other GI symptoms present
- [ ] Understand risks and benefits
- [ ] Can afford the cost
- [ ] Access to experienced center
- [ ] Committed to follow-up
- [ ] Realistic expectations set
Alternatives to Consider
If FMT is not right for you:
Conclusion and Recommendations
Summary
FMT represents an innovative approach to Parkinson's disease that targets the gut-brain axis. Evidence supports:
- Safety: Generally safe with transient GI side effects
- Efficacy: Moderate motor improvement in some patients
- Best outcomes: Constipation relief, early-stage patients
- Need for more research: Larger trials needed
Clinical Recommendations
Consider FMT for PD patients who:
- Have early to mid-stage disease
- Have significant constipation
- Are motivated and understand risks/benefits
- Can afford the cost
- Advanced disease
- Contraindications as listed
- Unrealistic expectations
Future Outlook
FMT for PD is still in early development but shows promise:
- Positive signals from clinical trials
- Good safety profile
- Biologically plausible mechanism
- Need for larger, longer trials
As the field develops, FMT may become a standard adjunct therapy for PD, particularly for patients with prominent gastrointestinal symptoms.
Contraindications
- Severe immunocompromised state
- Active GI infection
- Recent GI surgery
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | therapeutics-fmt-parkinsons |
| kg_node_id | None |
| entity_type | therapeutic |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-460359ab2240 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-fmt-parkinsons'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-therapeutics-fmt-parkinsons?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[FMT for Parkinson's Disease](http://scidex.ai/artifact/wiki-therapeutics-fmt-parkinsons)
http://scidex.ai/artifact/wiki-therapeutics-fmt-parkinsons